CSTL FINANCIAL STATEMENTS

Castle Biosciences Inc — balance sheet, income statement and cash flow trends

CSTLCastle Biosciences Inc

🇺🇸 USA · NASDAQ · Healthcare · Diagnostics & Research

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue339.9 M $-2.1%

Gross Profit262 M $-7.9%

Operating Income-33.3 M $—

EBITDA-725.7 K $-101.8%

Net Income-12.8 M $—

Peer Comparison· Diagnostics & Research

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CSTL	-2.1%	77.1%	-0.2%	-3.8%
GENIL	16.3%	23.4%	14.3%	4.0%
RYM	215.1%	-5.9%	-21.8%	-60.1%
SNZ	13.3%	42.8%	47.9%	72.0%
GSK	4.0%	72.7%	35.3%	17.8%
ECILC	-2.3%	34.3%	14.8%	-3.6%
Industry median	9.1%	53.0%	18.8%	6.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CSTL	-2.1%	77.1%	-0.2%	-3.8%
FLGT	9.5%	38.7%	-18.3%	-23.0%
MYGN	-0.3%	70.0%	-40.3%	-48.2%
OPK	-15.7%	22.7%	-6.0%	-36.6%
NEO	10.9%	42.1%	-4.5%	-13.3%
CDNA	19.2%	68.6%	2.6%	-2.0%
Industry median	9.1%	53.0%	18.8%	6.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity461.4 M $84%
Current Liabilities48.8 M $9%
Long-term Liabilities37.6 M $7%

Key Figures

YoY change

Total Assets547.8 M $+9.2%

Total Liabilities86.4 M $+40.7%

Total Equity461.4 M $+4.8%

Cash & ST Investments261.7 M $-4.9%

Total Debt36.7 M $+42.1%

Net Debt-27 M $—

Peer Comparison· Diagnostics & Research

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CSTL	6.75	8.0%	310.00	84.2%
GENIL	1.33	41.0%	1.10	52.6%
RYM	0.55	39.0%	-6.24	33.2%
SNZ	0.34	59.6%	11.44	36.0%
GSK	0.79	106.7%	1.35	28.4%
ECILC	1.73	5.9%	-0.10	81.0%
Industry median	1.87	49.3%	1.92	50.1%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CSTL	6.75	8.0%	310.00	84.2%
FLGT	5.31	1.0%	4.55	90.8%
MYGN	2.40	62.7%	-0.26	50.1%
OPK	3.61	33.0%	-1.59	64.9%
NEO	4.42	49.3%	-7.82	61.5%
CDNA	3.40	7.8%	-15.21	76.3%
Industry median	1.87	49.3%	1.92	50.1%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow48.3 M $-26.5%

Capital Expenditures43.7 M $+82.9%

Free Cash Flow4.5 M $-89.2%

Dividends Paid——

Peer Comparison· Diagnostics & Research

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CSTL	14.2%	1.3%	12.9%	-376.0%
GENIL	6.4%	-6.7%	4.8%	162.4%
RYM	36.5%	31.3%	5.2%	-60.7%
SNZ	137.8%	87.4%	50.4%	191.5%
GSK	23.0%	15.3%	7.7%	129.5%
ECILC	13.9%	16.1%	7.1%	-391.0%
Industry median	16.3%	9.7%	4.5%	110.1%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CSTL	14.2%	1.3%	12.9%	-376.0%
FLGT	-28.1%	-35.3%	7.2%	122.1%
MYGN	0.3%	-2.8%	3.1%	-0.6%
OPK	-28.1%	-30.0%	1.9%	76.7%
NEO	3.0%	-0.7%	3.7%	-22.6%
CDNA	17.7%	15.8%	1.9%	-890.4%
Industry median	16.3%	9.7%	4.5%	110.1%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on CSTL

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.